Group 1 - The chairman of Huarun Pharmaceutical, Zhang Li, has resigned due to personal reasons, and this matter is unrelated to the company or its operations [1][3] - The company has appointed director Hou Ruipeng to act as the chairman and legal representative until a new chairman is elected [1][3] - Zhang Li was appointed as chairman on April 29 this year and has served for less than four months before being placed under residential surveillance [3] Group 2 - Huarun Pharmaceutical reported a revenue of 624 million yuan for the first half of 2025, a year-on-year decrease of 19.1%, and a net profit attributable to shareholders of 37.33 million yuan, down 49.0% [3][4] - The decline in revenue and gross profit is attributed to medical reform policies, including price controls and centralized procurement, which have led to price reductions for some products [3] - Despite an overall decline in business, key products such as peritoneal dialysis fluid and blood filtration replacement fluid have shown steady growth, with peritoneal dialysis fluid sales increasing by 45.80% to 16.87 million bags [4]
突发!36岁董事长辞职并受监视居住,才当选不到4个月